DRTSThe enrollment finish line
Alpha Tau just crossed a key milestone: all 88 patients are now enrolled in its U.S. pivotal ReSTART trial for Alpha DaRT, the company’s intratumoral alpha-radiation therapy for recurrent cutaneous squamous cell carcinoma.
That may sound like clinical-trial housekeeping, but in biotech/device land, getting the last patient in the door is a big deal. No patients, no data. No data, no shot at FDA approval. And Alpha Tau is already pushing ahead with its PMA modular application process, which means the company is trying to keep the approval train moving instead of letting it sit at the station.
Why investors should care
This is Alpha Tau’s first U.S. pivotal study to complete enrollment, so it’s a legit de-risking moment. The company says the trial builds on earlier skin-cancer work in Israel, Italy, France, and the U.S., giving Alpha DaRT a thicker clinical dossier as it goes after pre-market approval.
A few things to keep in mind:
- recurrent cSCC is the second most common skin cancer, so this isn’t a tiny niche
- the target patients have already burned through surgery and conventional options, which is exactly where new therapies can shine
- the FDA has already given Alpha DaRT Breakthrough Device Designation, a nice little badge of honor that doesn’t guarantee success but definitely helps with the story
The long road to FDA land
Enrollment is not approval, of course. It’s just the next necessary step in a process that can feel a lot like assembling IKEA furniture with a missing Allen wrench. But for a small medtech name, each milestone matters because it sharpens the timeline between “interesting science project” and “actual revenue opportunity.”
If the data eventually support approval, Alpha Tau could have a much cleaner path to commercialization in a large, persistent cancer category with obvious unmet need. Big picture: the company is still in prove-it mode, but today’s update shows the Alpha DaRT program is moving from theory into the part of the story Wall Street actually cares about — the part with patients, endpoints, and FDA paperwork.